In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Overcoming Disaster: What Biotechs Do When A Lead Asset Fails

Executive Summary

Drug candidates fail at an alarming rate. For biotechs that seemingly have their entire future - and tens of millions of investor dollars - tied up in one compound or one clinical trial, failure of a lead asset can mean certain, sudden death. Meet four small companies that had another plan.
Advertisement

Related Content

Financings Of The Fortnight: Haircuts And Postponements Increasing As IPO Burst Slows Down
With Kolltan, Kinase Veteran Schlessinger Turns To Antibodies
AstraZeneca Opts Out Of Targacept Schizophrenia Program
AstraZeneca Drops Targacept's Failed ADHD Drug
Infinity/Purdue: The Challenge of Reprising Roche/Genentech
Infinity/Purdue: The Challenge of Reprising Roche/Genentech
Alzheimer's R&D: Tweaking Venture's Risk-Reward Ratio

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003477

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel